This website contains age-restricted materials. If you are over the age of 18 years or over the age of majority in the location from where you are accessing this website by entering the website you hereby agree to comply with all the TERMS AND CONDITIONS
By clicking on the “Agree” button, and by entering this website you acknowledge and agree that you are not offended by nudity and explicit depictions of sexual activity.
(Replace placeholder dates/sources with real citations when you locate them.) | Jurisdiction | Current Status | Notes | |--------------|----------------|-------| | United States (DEA) | Not scheduled (as of 2024) but under “monitoring” | May become Schedule I if evidence of abuse grows. | | European Union | Not listed in the EU Early Warning System (EWS) | Some member states have provisional bans. | | Canada | Not a controlled substance | Health Canada monitoring for adverse reports. | | Australia | Not scheduled, but “analogue” provisions could apply | Enforcement varies by state. |
If peer‑reviewed data are scarce, note that most information comes from pre‑prints, conference abstracts, or anecdotal reports. | Date | Source | Development | |------|--------|-------------| | Month 2024 | Journal of Emerging Psychoactive Substances | First‑time crystal structure resolved; potential for SAR studies. | | Month 2024 | Regulatory bulletin (e.g., DEA, EMA) | Added to the “emerging concern” list for monitoring. | | Month 2023 | Online forum analysis | Spike in online mentions; suggests growing user interest. | | Month 2023 | Patent filing (US 2023/XXXXX) | Claims novel synthetic route using inexpensive precursors. | sxyprn newest
Apra Shy Updates
(Replace placeholder dates/sources with real citations when you locate them.) | Jurisdiction | Current Status | Notes | |--------------|----------------|-------| | United States (DEA) | Not scheduled (as of 2024) but under “monitoring” | May become Schedule I if evidence of abuse grows. | | European Union | Not listed in the EU Early Warning System (EWS) | Some member states have provisional bans. | | Canada | Not a controlled substance | Health Canada monitoring for adverse reports. | | Australia | Not scheduled, but “analogue” provisions could apply | Enforcement varies by state. |
If peer‑reviewed data are scarce, note that most information comes from pre‑prints, conference abstracts, or anecdotal reports. | Date | Source | Development | |------|--------|-------------| | Month 2024 | Journal of Emerging Psychoactive Substances | First‑time crystal structure resolved; potential for SAR studies. | | Month 2024 | Regulatory bulletin (e.g., DEA, EMA) | Added to the “emerging concern” list for monitoring. | | Month 2023 | Online forum analysis | Spike in online mentions; suggests growing user interest. | | Month 2023 | Patent filing (US 2023/XXXXX) | Claims novel synthetic route using inexpensive precursors. |
